Biolegend, 577914, Cell-Vive™ GMP Recombinant Human IL-34 (carrier-free)
25microg
Catalog Number: 577914
Send an RFQ.
Category
Loading…
| Source | Human IL-34, amino acid (Asn21-Pro242) (Accession: # NM_152456.2), with carboxy terminus 10H tag, was expressed in CHO cells. |
|---|---|
| Molecular Mass | The 235 amino acid recombinant protein has a predicted molecular mass of 26.7 kD. The DTT-reduced protein migrates at approximately 40 kD, and the non-reduced protein migrates with slightly greater mobility by SDS-PAGE. The predicted N-terminal amino acid is Asn. |
| N-terminalSequence Analysis | Asn-Glu-Pro-Leu-Glu-Met-Trp-Pro-Leu-Thr |
| Purity | ≥ 95%, as determined by Coomassie stained SDS-PAGE |
| Formulation | 0.1 µm filtered protein solution is in 10mM Na2HPO4, 0.5M NaCl, pH 7.4. |
| Endotoxin Level | Less than or equal to 0.1 EU per μg protein as determined by the LAL method. |
| Residual Host Cell Protein Content | ≤ 0.500 ng/μg by ELISA |
| Concentration | 25 µg and 100 µg sizes are at 0.5 mg/mL. |
| Storage & Handling | Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week or stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles. |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Activity | Human IL-34 induces MCP-1 (CCL2) production in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. The ED50 for this effect is 4 - 20 ng/mL. |
|---|
| Application | Bioassay |
|---|
| Application Notes | BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected]. |
|---|
| Disclaimer | BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products. |
|---|
| Structure | Homodimer |
|---|
| Distribution | IL-34 mRNA is expressed in different tissues, including spleen, heart, brain, lung, liver, kidney, thymus, testes, ovary, small intestine, prostate, and colon. |
|---|
| Function | IL-34 increases monocyte's viability, induces macrophage proliferation, and synergizes with other cytokines to generate macrophages and osteoclasts from cultured progenitors. IL-34 promotes the formation of the colony-forming unit-macrophage (CFU-M) in human bone marrow culture. IL-34 supports RANKL-induced osteoclastogenesis by promoting the adhesion and proliferation of osteoclast progenitors. Human IL-34 promotes the osteoclast differentiation from peripheral blood mononucleated cells. In addition, systematic administration of IL-34 to mouse increases the number of CD11b+ cells and reduces bone mass. IL-1β and TNF-α induce the expression of interleukin-34 mRNA in osteoblast. IL-34 is induced in macrophages infected with equine infectious anemia virus (EIAV). |
|---|
| Interaction | Macrophages, monocytes, myeloid cells |
|---|
| Ligand/Receptor | CSF-1R |
|---|
| Bioactivity | Induces cytokine production in PBMCs. |
|---|
| Biology Area | Immunology, Innate Immunity, Stem Cells |
|---|
| Molecular Family | Cytokines/Chemokines |
|---|
| Antigen References | Clanchy F, et al. 2006. J Leukoc Biol. 79:757-66. Lin H, et al. 2008. Science. 320:807-11. Chihara T, et al. 2010. Cell Death Differ. 17:1917-27. Wei S, et al. 2010. J Leukoc Biol. 88:495-505. Eda H, et al. 2010. Cytokine. 52:215-20. Covaleda L, et al. 2010. Virology. 397:217-23. Chen Z, et al. 2011. PLoS One. 6:e18689. Cai H, et al. 2022. J Obstet Gynecol Res. 48:973. Huang X, et al. 2021. J Neuroimminol. 358:577652. |
|---|
| Gene ID | 146433 |
|---|
| UniProt | View information about IL-34 on UniProt.org |
|---|
| Other Names | Interleukin-34 |
|---|
